SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Neogen Corp – ‘8-K’ for 1/4/21

On:  Wednesday, 1/6/21, at 8:35pm ET   ·   As of:  1/7/21   ·   For:  1/4/21   ·   Accession #:  1193125-21-3464   ·   File #:  0-17988

Previous ‘8-K’:  ‘8-K’ on / for 12/22/20   ·   Next:  ‘8-K’ on / for 3/2/21   ·   Latest:  ‘8-K’ on / for 3/23/21

Magnifying glass tilted right emoji
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/07/21  Neogen Corp                       8-K:2,9     1/04/21   11:135K                                   Donnelley … Solutions/FA

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     23K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     10K 
 7: R1          Document and Entity Information                     HTML     41K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 6: XML         XBRL Instance -- d102117d8k_htm                      XML     12K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- neog-20210104_lab                     XML     47K 
 5: EX-101.PRE  XBRL Presentations -- neog-20210104_pre              XML     30K 
 3: EX-101.SCH  XBRL Schema -- neog-20210104                         XSD     12K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               10±    17K 
11: ZIP         XBRL Zipped Folder -- 0001193125-21-003464-xbrl      Zip     11K 

‘8-K’   —   Current Report

This is an HTML Document rendered as filed.  [ Alternative Formats ]

 i NEOGEN CORP  i false  i 0000711377 0000711377 2021-01-04 2021-01-04





Washington, D.C. 20549



FORM  i 8-K




Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  i January 4, 2021




(Exact name of registrant as specified in its charter)




 i Michigan    i 0-17988    i 38-2367843

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


 i 620 Lesher Place  i Lansing,  i Michigan    i 48912
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code  i 517- i 372-9200

(Former name or former address, if changed since last report.)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   i 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 2.01

Completion of Acquisition of Disposition of Assets

On January 4, 2021, Neogen Corporation announced that it had acquired Ireland-based Megazyme, Ltd. — a supplier of analytical solutions used by quality control laboratories in the global food and beverage industries. Megazyme, founded in 1988, develops and refines analytical methods used to measure the carbohydrates and enzymes in grain, cereal, wine, dairy and other food products, that affect quality. Megazyme will continue to operate as a standalone business in Bray, Ireland, and will be managed through Neogen’s European operations in Scotland.

A copy of the press release is attached as Exhibit 99.1 to this report. This Form 8-K and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not incorporated by reference into any filing of the Registrant, whether made before or after the date of this report, regardless of any general incorporation language in the filing.


Item 9.01

Financial Statements and Exhibits

(d) Exhibits



Press Release dated January 4, 2021

104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: January 6, 2021      

/s/ Steven J. Quinlan

      Steven J. Quinlan
      Vice President & CFO

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed as of:1/7/21
Filed on:1/6/214
For Period end:1/4/21
 List all Filings 
Filing Submission 0001193125-21-003464   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2021 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 6, 5:06:08.0am ET